Jim Porter, Nuvalent CEO
Taking on Big Pharma rivals, biotech startup unveils first-in-human data on ROS1 drug
Nuvalent set out to show that by leveraging structure-based drug design and a bit of chemistry whiz out of its Harvard founder’s lab, it can …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
